Evidence that the plant cannabinoid ¿9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist

Adele Thomas, Lesley Ann Stevenson, Kerrie Wease, Martin Price, Gemma Baillie, Ruth Alexandra Ross, Roger Guy Pertwee

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

1. Delta(9)-tetrahydrocannabivarin (THCV) displaced [H-3]CP55940 from specific binding sites on mouse brain and CHO-hCB(2) cell membranes (K-i = 75.4 and 62.8 nm, respectively).

2 THCV (1 mu M) also antagonized CP55940-incluced stimulation of [S-35]GTP S binding to these membranes (apparent K-B = 93.1 and 10.1 nM, respectively).

3 In the mouse vas deferens, the ability of Delta(9)-tetrahydrocannabinol (THC) to inhibit electrically evoked contractions was antagonized by THCV, its apparent K-B-value (96.7nm) approximating the apparent K-B-values for its antagonism of CP55940- and R-(+)-WIN55212-induced stimulation of [S-35]GTP gamma S binding to mouse brain membranes.

4 THCV also antagonized R-(+)-WIN55212, anandamide, methanandamide and CP55940 in the vas deferens, but with lower apparent KB-values (1.5, 1.2, 4.6 and 10.3 nm, respectively).

5 THCV (100nm) did not oppose clonidine, capsaicin or (-)-7-liydroxy-cannabidiol-dimethylheptyl-induced inhibition of electrically evoked contractions of the vas deferens.

6 Contractile responses of the vas deferens to phenylephrine hydrochloride or beta,gamma-methylene-ATP were not reduced by 1 mu m THCV or R-(+)-WIN55212, suggesting that THCV interacts with R-(+)WIN55212 at prejunctional sites.

7 At 32 mu m, THCV did reduce contractile responses to phenylephrine hydrochloride and beta,gamma-methylene-ATP, and above 3 pm it inhibited electrically evoked contractions of the vas deferens in an SR141716A-independent manner.

8 In conclusion, THCV behaves as a competitive CB1 and CB2 receptor antagonist. In the vas deferens, it antagonized several cannabinoids more potently than THC and was also more potent against CP55940 and R-(+)-WIN55212 in this tissue than in brain membranes. The bases of these agonist- and tissue-dependent effects remain to be established.

Original languageEnglish
Pages (from-to)917-926
Number of pages9
JournalBritish Journal of Pharmacology
Volume146
Issue number7
DOIs
Publication statusPublished - Dec 2005

Keywords

  • Delta(9)-tetrahydrocannabivarin
  • Delta(9)-tetrahydrocannabinol
  • R-(+)-WIN55212
  • anandamide
  • methanandamide
  • CP55940
  • cannabinoids
  • mouse vas deferens
  • CB1 receptor antagonist
  • CB2 receptor antagonist
  • nonadrenaline release
  • selective antagonist
  • inverse agonism
  • nervous-system
  • pharmacology
  • acetylcholine
  • modulation
  • non-CB1

Cite this

Evidence that the plant cannabinoid ¿9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. / Thomas, Adele; Stevenson, Lesley Ann; Wease, Kerrie; Price, Martin; Baillie, Gemma; Ross, Ruth Alexandra; Pertwee, Roger Guy.

In: British Journal of Pharmacology, Vol. 146, No. 7, 12.2005, p. 917-926.

Research output: Contribution to journalArticle

Thomas, Adele ; Stevenson, Lesley Ann ; Wease, Kerrie ; Price, Martin ; Baillie, Gemma ; Ross, Ruth Alexandra ; Pertwee, Roger Guy. / Evidence that the plant cannabinoid ¿9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. In: British Journal of Pharmacology. 2005 ; Vol. 146, No. 7. pp. 917-926.
@article{68ca01c548934e379242f44310d23aea,
title = "Evidence that the plant cannabinoid ¿9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist",
abstract = "1. Delta(9)-tetrahydrocannabivarin (THCV) displaced [H-3]CP55940 from specific binding sites on mouse brain and CHO-hCB(2) cell membranes (K-i = 75.4 and 62.8 nm, respectively).2 THCV (1 mu M) also antagonized CP55940-incluced stimulation of [S-35]GTP S binding to these membranes (apparent K-B = 93.1 and 10.1 nM, respectively).3 In the mouse vas deferens, the ability of Delta(9)-tetrahydrocannabinol (THC) to inhibit electrically evoked contractions was antagonized by THCV, its apparent K-B-value (96.7nm) approximating the apparent K-B-values for its antagonism of CP55940- and R-(+)-WIN55212-induced stimulation of [S-35]GTP gamma S binding to mouse brain membranes.4 THCV also antagonized R-(+)-WIN55212, anandamide, methanandamide and CP55940 in the vas deferens, but with lower apparent KB-values (1.5, 1.2, 4.6 and 10.3 nm, respectively).5 THCV (100nm) did not oppose clonidine, capsaicin or (-)-7-liydroxy-cannabidiol-dimethylheptyl-induced inhibition of electrically evoked contractions of the vas deferens.6 Contractile responses of the vas deferens to phenylephrine hydrochloride or beta,gamma-methylene-ATP were not reduced by 1 mu m THCV or R-(+)-WIN55212, suggesting that THCV interacts with R-(+)WIN55212 at prejunctional sites.7 At 32 mu m, THCV did reduce contractile responses to phenylephrine hydrochloride and beta,gamma-methylene-ATP, and above 3 pm it inhibited electrically evoked contractions of the vas deferens in an SR141716A-independent manner.8 In conclusion, THCV behaves as a competitive CB1 and CB2 receptor antagonist. In the vas deferens, it antagonized several cannabinoids more potently than THC and was also more potent against CP55940 and R-(+)-WIN55212 in this tissue than in brain membranes. The bases of these agonist- and tissue-dependent effects remain to be established.",
keywords = "Delta(9)-tetrahydrocannabivarin, Delta(9)-tetrahydrocannabinol, R-(+)-WIN55212, anandamide, methanandamide, CP55940, cannabinoids, mouse vas deferens, CB1 receptor antagonist, CB2 receptor antagonist, nonadrenaline release, selective antagonist, inverse agonism, nervous-system, pharmacology, acetylcholine, modulation, non-CB1",
author = "Adele Thomas and Stevenson, {Lesley Ann} and Kerrie Wease and Martin Price and Gemma Baillie and Ross, {Ruth Alexandra} and Pertwee, {Roger Guy}",
year = "2005",
month = "12",
doi = "10.1038/sj.bjp.0706414",
language = "English",
volume = "146",
pages = "917--926",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Evidence that the plant cannabinoid ¿9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist

AU - Thomas, Adele

AU - Stevenson, Lesley Ann

AU - Wease, Kerrie

AU - Price, Martin

AU - Baillie, Gemma

AU - Ross, Ruth Alexandra

AU - Pertwee, Roger Guy

PY - 2005/12

Y1 - 2005/12

N2 - 1. Delta(9)-tetrahydrocannabivarin (THCV) displaced [H-3]CP55940 from specific binding sites on mouse brain and CHO-hCB(2) cell membranes (K-i = 75.4 and 62.8 nm, respectively).2 THCV (1 mu M) also antagonized CP55940-incluced stimulation of [S-35]GTP S binding to these membranes (apparent K-B = 93.1 and 10.1 nM, respectively).3 In the mouse vas deferens, the ability of Delta(9)-tetrahydrocannabinol (THC) to inhibit electrically evoked contractions was antagonized by THCV, its apparent K-B-value (96.7nm) approximating the apparent K-B-values for its antagonism of CP55940- and R-(+)-WIN55212-induced stimulation of [S-35]GTP gamma S binding to mouse brain membranes.4 THCV also antagonized R-(+)-WIN55212, anandamide, methanandamide and CP55940 in the vas deferens, but with lower apparent KB-values (1.5, 1.2, 4.6 and 10.3 nm, respectively).5 THCV (100nm) did not oppose clonidine, capsaicin or (-)-7-liydroxy-cannabidiol-dimethylheptyl-induced inhibition of electrically evoked contractions of the vas deferens.6 Contractile responses of the vas deferens to phenylephrine hydrochloride or beta,gamma-methylene-ATP were not reduced by 1 mu m THCV or R-(+)-WIN55212, suggesting that THCV interacts with R-(+)WIN55212 at prejunctional sites.7 At 32 mu m, THCV did reduce contractile responses to phenylephrine hydrochloride and beta,gamma-methylene-ATP, and above 3 pm it inhibited electrically evoked contractions of the vas deferens in an SR141716A-independent manner.8 In conclusion, THCV behaves as a competitive CB1 and CB2 receptor antagonist. In the vas deferens, it antagonized several cannabinoids more potently than THC and was also more potent against CP55940 and R-(+)-WIN55212 in this tissue than in brain membranes. The bases of these agonist- and tissue-dependent effects remain to be established.

AB - 1. Delta(9)-tetrahydrocannabivarin (THCV) displaced [H-3]CP55940 from specific binding sites on mouse brain and CHO-hCB(2) cell membranes (K-i = 75.4 and 62.8 nm, respectively).2 THCV (1 mu M) also antagonized CP55940-incluced stimulation of [S-35]GTP S binding to these membranes (apparent K-B = 93.1 and 10.1 nM, respectively).3 In the mouse vas deferens, the ability of Delta(9)-tetrahydrocannabinol (THC) to inhibit electrically evoked contractions was antagonized by THCV, its apparent K-B-value (96.7nm) approximating the apparent K-B-values for its antagonism of CP55940- and R-(+)-WIN55212-induced stimulation of [S-35]GTP gamma S binding to mouse brain membranes.4 THCV also antagonized R-(+)-WIN55212, anandamide, methanandamide and CP55940 in the vas deferens, but with lower apparent KB-values (1.5, 1.2, 4.6 and 10.3 nm, respectively).5 THCV (100nm) did not oppose clonidine, capsaicin or (-)-7-liydroxy-cannabidiol-dimethylheptyl-induced inhibition of electrically evoked contractions of the vas deferens.6 Contractile responses of the vas deferens to phenylephrine hydrochloride or beta,gamma-methylene-ATP were not reduced by 1 mu m THCV or R-(+)-WIN55212, suggesting that THCV interacts with R-(+)WIN55212 at prejunctional sites.7 At 32 mu m, THCV did reduce contractile responses to phenylephrine hydrochloride and beta,gamma-methylene-ATP, and above 3 pm it inhibited electrically evoked contractions of the vas deferens in an SR141716A-independent manner.8 In conclusion, THCV behaves as a competitive CB1 and CB2 receptor antagonist. In the vas deferens, it antagonized several cannabinoids more potently than THC and was also more potent against CP55940 and R-(+)-WIN55212 in this tissue than in brain membranes. The bases of these agonist- and tissue-dependent effects remain to be established.

KW - Delta(9)-tetrahydrocannabivarin

KW - Delta(9)-tetrahydrocannabinol

KW - R-(+)-WIN55212

KW - anandamide

KW - methanandamide

KW - CP55940

KW - cannabinoids

KW - mouse vas deferens

KW - CB1 receptor antagonist

KW - CB2 receptor antagonist

KW - nonadrenaline release

KW - selective antagonist

KW - inverse agonism

KW - nervous-system

KW - pharmacology

KW - acetylcholine

KW - modulation

KW - non-CB1

U2 - 10.1038/sj.bjp.0706414

DO - 10.1038/sj.bjp.0706414

M3 - Article

VL - 146

SP - 917

EP - 926

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 7

ER -